Biomedical subjects

J Bobes

Publications and source records attributed to J Bobes.

At least 37 records · Page 2Linked to original sources

PubMed1998

How is recovery from social anxiety disorder defined?

Recovery in social anxiety disorder (social phobia) is a poorly defined concept. Since the onset of social anxiety disorder typically occurs during adolescence, a time when social skills and academic attainment are of particular importance, recovery is difficult to assess. Assessment of global improvement over 3 domains--symptoms, functionality, and well-being or overall severity of illness--is needed. This article describes currently available rating scales for social anxiety and uses data from clinical studies to assess whether improvement can be defined quantitatively in terms of scores on these rating scales. The main criteria have changed little over the past few years, with most investigators looking for a prespecified response on a single generic or specific rating scale for clinical severity. A better approach may be to employ a multiaxial system that uses a number of rating scales to measure both global and specific symptoms, disability, and quality of life.

Clinical Trials as Topic↗

PubMed1998

Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety.

OBJECTIVE: The goal of this consensus statement is to provide primary care clinicians with a better understanding of management issues in social anxiety disorder (social phobia) and guide clinical practice with recommendations for appropriate pharmacotherapy. PARTICIPANTS: The 4 members of the International Consensus Group on Depression and Anxiety were James C. Ballenger (chair), Jonathan R. T. Davidson, Yves Lecrubier, and David J. Nutt. Other faculty invited by the chair were Julio Bobes, Deborah C. Beidel, Yukata Ono, and Herman G. M. Westenberg. EVIDENCE: The consensus statement is based on the 7 review papers published in this supplement and on the scientific literature relevant to the issues reviewed in these papers. CONSENSUS PROCESS: The group met over a 2-day period. On day 1, the group discussed each review paper, and the chair identified key issues for further debate. On day 2, the group discussed these issues to arrive at a consensus view. After the group meetings, the consensus statement was drafted by the chair and approved by all attendees. CONCLUSIONS: The consensus statement underlines the importance of recognizing social anxiety disorder and provides recommendations on how it may be distinguished from other anxiety disorders. It proposes definitions for response and remission and considers appropriate management strategies. Selective serotonin reuptake inhibitors are recommended as first-line therapy, and effective treatment should be continued for at least 12 months. Long-term treatment is indicated if symptoms are unresolved, the patient has a comorbid condition or a history of relapse, or there was an early onset of the disorder.

Anxiety Disorders↗

PubMedDate not supplied

Brain glucose metabolism in borderline personality disorder.

We searched for regional cerebral metabolic disturbances in patients with borderline personality disorder (BPD). Ten inpatients with BPD, no current DSM-IIIR Axis I diagnosis and free of any psychotropic substances, were compared with 15 age-matched control subjects using positron emission tomography with 2-deoxy-2-[18F]fluoro-D-glucose and semiquantitative analysis of regional glucose metabolic activity. We found relative hypometabolism in patients with borderline personality disorder at the level of the premotor and prefrontal cortical areas, the anterior part of the cingulate cortex and the thalamic, caudate and lenticular nuclei. This study shows significant cerebral metabolic disturbances in patients with borderline personality disorder. These metabolic disturbances, which are similar to some of those described in other psychiatric entities, may help to understand the characteristic clinical aspects of this disorder.

Adult↗

PubMedDate not supplied

Validation of the Spanish version of the Changes in Sexual Functioning Questionnaire (CSFQ).

The aim of this study is to adapt and validate the Changes in Sexual Functioning Questionnaire (CSFQ) in Spanish. The CSFQ was administered to 206 depressed patients in different Spanish cities, to 326 health sciences students at the University of Oviedo, and to 48 workers undergoing routine health check-ups. The Hamilton Depression Rating Scale (HAM-D) was administered to the depressed patients. The average time spent answering the CSFQ was 15.19 minutes. The CSFQ discriminated the depressed patients from the workers and university students. In the three areas of reliability (internal, test-retest, and inter-rater), the coefficients obtained were greater than 0.80. The factor analysis demonstrated differences in the internal construct of the American CSFQ and its Spanish equivalent. The psychometrc properties of the Spanish version of the CSFQ indicate that it is a valid instrument for clinical use in treating depressed patients.

Adult↗

PubMedDate not supplied

Evaluating changes in sexual functioning in depressed patients: sensitivity to change of the CSFQ.

Accurately evaluating alterations in sexual functioning requires a validated instrument that measures clinically relevant change over time. One-hundred one depressed patients from 15 Spanish out-patient clinics completed the Changes in Sexual Functioning Questionnaire (CFSQ; Clayton, McGarvey, & Clavet, 1997) at baseline and after 6 months of treatment with fluoxetine, nefazodone, paroxetine, or venlafaxine. Sexual desire/interest showed a nearly substantial floor effect (30% of patients indicated the maximum score) for women in the nefazodone group at baseline and in the paroxetine group at final visit. The percentage of dimensions recording change was greater for women (80%) than for men (20%) in the nefazodone group (improving changes) and greater for men (40%) than for women (20%) in the paroxetine group (worsening changes). Highest effect sizes were found on sexual desire/frequency with improvement in women in the nefazodone group (SES = 0.49), and on orgasm/ejaculation with worsening in men in the paroxetine group (SES = -1.45). In conclusion, the CSFQ is sensitive to bidirectional changes and is appropriate for measuring sexual dysfunction.

Antidepressive Agents↗

PubMedDate not supplied

Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study.

Atypical antipsychotics seem to differ mainly in their tolerability profile. The aim of this cross-sectional study, the Estudio de Investigaci n de Resultados en Esquizofrenia (Outcomes Research Study in Schizophrenia; EIRE study), was to assess in a clinical setting the frequency of several side-effects related to haloperidol, risperidone, olanzapine, and quetiapine. This article addresses sexual dysfunction and other reproductive side-effects (gynecomastia, menorrhage, amenorrhea, and galactorrhea). We recruited outpatients diagnosed with schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders (DSM-IV; American Psychiatric Association, 1994) criteria and who had received a single antipsychotic (risperidone, olanzapine, quetiapine, or haloperidol) for at least 4 weeks. During a single visit, we collected data, including demographic and clinical characteristics, current antipsychotic and concomitant treatment, and adverse effects listed in a modified version of the UKU Scale. We used a Chi-squared test to determine pairs comparisons of the frequency of adverse reactions between treatments. To estimate risk of a given adverse reaction with a given treatment, we used a logistic regression method. We assessed 636 evaluable patients out of 669 recruited. Frequency of sexual dysfunction was high with haloperidol (38.1%) and also with olanzapine (35.3%), quetiapine (18.2%), and risperidone (43.2%). We found the frequency of other reproductive side-effects to be relatively low with all four drugs: haloperidol (6.9%), olanzapine (6.4%), quetiapine (2.7%), and risperidone (11.7%). Sexual dysfunction appeared to be dose-related with haloperidol, risperidone, and olanzapine. Risperidone and olanzapine showed a higher risk of sexual dysfunction and other reproductive sideeffects than haloperidol. Quetiapine showed a lower risk of sexual dysfunction during short-term treatment (< 12 weeks). However, data on longer-term treatment (> 12 weeks) are lacking. Our results suggest that none of the atypical antipsychotics that we studied significantly improved sexual dysfunction and other reproductive side-effects of the conventional antipsychotic, haloperidol, in stabilized patients during long-term treatment. Quetiapine appears to improve this profile during short-term treatment; however, longterm data, with larger samples, are required with this latter drug.

Adult↗

PubMedDate not supplied

[Long term evolution of the incapacity in schizophrenic patients in maintenance treatment with risperidone].

OBJECTIVE: To determine the evolution of the degree of long term disability (8 months) in a group of schizophrenic outpatients undergoing monotherapy with risperidone. DESIGN, An observational multicentre study of 8 months follow up. PATIENTS: 354 patients with schizophrenic disorder (ICD-10). EVALUATION: Baseline, 2, 4 and 8 months. INSTRUMENTS: BPRS, CGI, UKU, WHO/DAS-S. RESULTS: a significant decrease in both the global scores and in each of the 4 areas of disability. Improvement in disability depends to a large degree on the improvement of the disorder as shown on the BPRS and CGI. After 8 months, those patients with paranoid subtype and the less severe ones (BPRS and CGI) showed a considerably lesser degree of disability. The final level of disability (square root = 0,61) is narrowly related to the baseline level of disability, the 3 clusters of the final BPRS, the final CGI, gender and the subtype of schizophrenia.

Adult↗

PubMedDate not supplied

[Seville Quality of Life Questionnaire: historic outlook of its establishment].

We describe how we developed a new instrument for measuring quality of life, the Seville Quality of Life Questionnaire (SQCQ), and the results we obtained when we applied it to a group of schizophrenic patients. The questionnaire was designed by a group of researchers who set out from the premise that the quality of life of schizophrenic patients is perceived differently from that of healthy people, and tried first of all to demarcate the kind of area which is abnormal in these patients. We then devised a set of items which were assessed for clarity and pertinence by a series of experts, and the questionnaire was assembled in the form of a set of statements, response to which is in the form of a Lickert-type 5-stage scale. The finished questionnaire was administered to 279 schizophrenic patients. At the same time, these patients were also evaluated using the AMDP Psychopathology Scale, the positive and negative symptoms evaluation scale (PANS), Lehman's structured quality of life interview (QOLY), Ruiz and Baca's quality of life questionnaire (QLQ), Camberwell's scale of needs analysis (CANr) and the WHO's handicap assessment scale (DDS). These questionnaires were used to judge the different types of validity of the Seville Questionnaire. The reliability of the questionnaire was measured using Cronbach's alpha coefficient (internal consistency: 0,85 scale of favourable aspects, 0,96 scale of unfavourable aspects). As far as validity was concerned, both scales of the questionnaire were found to have a high level of validity. We also examined the extent to which the psychopathological disorders affected the quality of the schizophrenic person's life, the extent to which his/her needs were being met by the health services, and the patient's degree of disability. From the results obtained, we can say that the SQCQ is a reliable and valid instrument, which is sufficiently sensitive to the clinical changes produced in the course of the natural history of the disease. The SQCQ stands out from the other quality of life questionnaires in that it takes into account aspects of the disease which the patient him/herself is aware of as affecting his/her quality of life.

Humans↗

PubMedDate not supplied

[Validation of the Spanish version of the social adaptation scale in depressive patients].

INTRODUCTION: The Social Adaptation Self-evaluation Scale (SASS) allows a very easy evaluation of the individual's perspective about himself and his environment, together with his behaviour and social motivation. Taking into account that social maladjustment is high prevalent and well documented for depressed subjects and it is one of the most limiting aspects of their global performance, the aim of the present work is to validate the Spanish version of SASS for its application in subjects diagnosed as suffering major depression (DSM-IV). METHODOLOGY: A cross sectional multicentre study was carried out by collecting information on 464 patients (34.7% men and 65.3% women range 18 to 65 years), which included their answers to the scale and relevant sociodemographic and clinical variables. RESULTS: The principal component analysis corroborated the identification of 4 main factors: the first one being extrafamily relationships (31.4% of inertia); the second, work and leisure (7.6% of inertia); the third, social and cultural interests (5.6% of inertia); and the fourth factor, family relationships and behavioral strategies (5.5% of intertia). The scale has provided adequate reliability and validity indexes as well as sensitivity to the severity of the depressive episode. CONCLUSIONS: The Spanish version of the SASS has proven to be an adequate instrument for evaluating social adjustment in depressive subjects. However, future studies must corroborate its sensitivity to the effects of antidepressant treatment and potential differences between the antidepressant agents employed.

Adaptation, Psychological↗

PubMedDate not supplied

[Quality of life and disability in chronic schizophrenics treated with with risperidone and previously treated with depot neuroleptics].

OBJECTIVES: 1. Assess the evolution of disability and quality of life in schizophrenic patients treated with risperidone and who had received depot neuroleptics; 2. Evaluate risperidone efficiency; 3. Evaluate safety of this drug. METHOD: Post-marketing multicentric observational (8 months) surveillance study was carried out. PATIENTS: 109 schizophrenic patients (ICD-10 criteria). ASSESSMENTS: baseline and months 2, 4 and 8. INSTRUMENTS: SF-36, WHO/DDS-S, BPRS and CGI. Safety was evaluated by the UKU subscale for neurological side effects and spontaneous reports. RESULTS: statistically significant improvement of the mean scores of BPRS, CGI, WHO/DDS-S and SF-36 at 2, 4 and 8 months. There was a significant reduction in the total UKU subscale for neurological side effects scores from visit 1 (month 2) onwards. Risperidone was generally well tolerated by the study patients. From a total of 104 patients included, only 4 (3.8%) discontinued treatment due to adverse reactions. During the 8 months of study period, 87.6% of the patients did not suffer any adverse event; the resting 12.4 suffered one or more side effects. The most frequently reported adverse events according spontaneous reports were: anxiety and restlessness (n= 4; 3.8%), weight increase (n= 4; 3.8%), sexual disturbances (n= 4; 3.8%) and amenorrhea (n= 2; 1.9%) among others. CONCLUSION: the long-term treatment with risperidone has improved the disability and quality of life levels of a large group of schizophrenic patients previously treated with depot neuroleptics.

Adult↗

PubMedDate not supplied

[Factors associated with health related quality of life in patients undergoing renal replacement therapy].

The aim of this study was to investigate the sociodemographic and clinical variables which influence health-relate quality of life (HRQOL) of patients on renal replacement therapy (RRT). A cross-sectional study was carried out with a sample including all patients on hemodialysis (n = 170) and transplant patients (n = 210) of our region. The HRQOL assessment instruments used in this study were: the Spanish versions of the sickness impact profile (SIP) and the SF-36 health survey (SF-36). Sociodemographic and clinical data (including age at start of RRT, age at the interview, gender, hospital, socioeconomic level, educational level, living conditions, inclusion in transplant waiting list, renal disease diagnosis, time in any RRT, hemoglobin, hematocrit, serum urea, creatinine, proteins and albumin, hospital admissions and length of hospital stay during last year), a comorbidity index and the Karnofsky performance scale score step. To investigate which studied variables had independent influence over the HRQOL measures, logistic regression method was employed in the case of the SF-36, and multiple regression, in the case of the SIP. A model was adjusted step by step in each RRT method (hemodialysis and transplantation) for each dimension of the PCE (physical dimension, psychosocial dimension and total score), and for each component summary score of the SF-36 (physical and mental component summary). In patients on hemodialysis, variables associated with better HRQOL were: higher age, female gender, higher educational level, and better functional status; and variables associated with worse HRQOL were: higher number of hospital admissions, and higher comorbidity index. In transplant patients, variables associated with better HRQOL were: higher age and higher functional status; and variables associated with worse HRQOL were: longer time on dialysis before transplant, longer time with functioning transplant, and higher comorbidity index. Despite the independent influence on the HRQOL demonstrated for some of the studied variables, it seems that HRQOL assessment instruments scores may mainly depend on other non-studied variables, and it may be that these instruments evaluate other aspects of the patients which have not been taken into account until now.

Aged↗

PubMedDate not supplied

[Interpretation of health-related quality of life of patients on replacement therapy in end-stage renal disease].

UNLABELLED: STATEMENT: Older age is associated with a worse Health-Related Quality of Life (HRQOL) in patients with End-Stage Renal Disease (ESRD). The aim of this study is to demonstrate that differences on HRQOL between two groups of patients, defined according to age (< 65 years and > or = 65 years or elderly), change according to the form in which the results are analysed. METHODS: We evaluated the HRQOL of 170 patients undergoing hemodialysis and 210 transplant patients from Asturias (Spain), using the SF-36 Health Survey. Sociodemographic and clinical data, Karnofsky Scale and a Comorbidity Index were also collected. The raw scores of the SF-36 and the standardised scores according to age and gender were employed. RESULTS: The majority of elderly patients on hemodialysis lived alone, constituted a smaller percentage on the transplant waiting list, had a lower serum albumin and lower score of the Karnofsky Scale, than patients under 65 years. No differences were found in transplant patients. The raw scores on the SF-36 were less for the elderly patients on hemodialysis and transplant. The raw scores for elderly undergoing hemodialysis were less than those obtained by the general population, and raw scores for elderly transplant patients were similar or slightly greater. The standardized scores of the SF-36 were greater for the elderly in both treatment groups. CONCLUSIONS: Important differences exist in the evaluation of HRQOL differences between the two groups of age according to the method of analysing the results. The HRQOL of elderly patients is better than that of patients under 65 years of age.

Age Factors↗

PubMedDate not supplied

[Evaluation of the psychometric properties of the Spanish version of 5 questionnaires for the evaluation of post-traumatic stress syndrome].

AIM: To determine the psychometric properties of the Spanish versions of the following scales for assessing PTSD patients: TQ, CAPS-DX, DTS, TOP-8, and DGRP. METHODS: Data from 63 PTSD patients and 23 healthy subjects were analysed. Internal consistency and test-retest reliability (after 15 days) were calculated. Convergent validity was analysed by correlating subjects' scores with the number of symptoms (DSM-IV) and scores on the CGI scale. Discriminative capability was analysed by comparing TQ, CAPS-DX, DTS, TOP-8, and DGRP patients' scores with scores from healthy subjects, and between patients' subgroups according to the presence or absence of psychiatric comorbidity and to the degree of severity as determined by the CGI-S. RESULTS: CAPS-DX, DTS, TOP-8, and DGRP showed an adequate internal consistency (Cronbach alpha: 0.74-0.91) and all of them obtained ICC between 0.77 and 0.93. The five questionnaires were able to discriminate between patients and healty subjects, and between the patients' subgroups. CONCLUSIONS: The Spanish versions of the TQ, CAPS-DX, DTS, TOP-8, and DGRP have shown adequate reliability and validity for assessing PTSD patients in daily clinical practice. CAPS-DX seems to be more adequate a diagnostic and DTS a severity rating scale.

Adult↗

PubMedDate not supplied

[Quality of life of children: importance of its evaluation. Comparison of children in good health with those at risk (psychological, social, somatic)].

A multicentric study was performed in France and Spain: 490 children were evaluated with a previously validated questionnaire including open-ended questions and structured response format questions. Children are either in good health or suffering from somatic diseases, psychological problems or social difficulties; 38% of the children are Spanish, 62% are French; the questionnaire validation was checked again, and confirmed. Children are happy about their leisure, and unhappy when separated from their families. Among the factors affecting the answers to the structured format questions the most important are the social difficulties and to a lesser extent the psychological problems. Somatic diseases impair the child's quality of life in Spain. Children differ according to the country where they live. Among children in good health, Spanish children report a better quality of life than French children. Open-ended answers were only studied in France. They were very different when children with social difficulties or psychological problems filled out the questionnaire and were compared to children in good health or with somatic diseases. Both children with psychological and social difficulties mention more often the relationship domain. Children with social problems never mention their activities as a source of happiness.

Child↗

PubMedDate not supplied

[Risperidone: a real alternative for patients treated with depot neuroleptics].

OBJECTIVE: to determine the efficacy and tolerability of risperidone in schizophrenic outpatients. MATERIAL AND METHOD DESIGN: multicentre, observational, 6 month follow-up study. PATIENTS: 421 schizophrenic (ICD-10 criteria) outpatients previously treated with depot neuroleptics and who were switched from depot medication to risperidone due to inefficacy and/or low tolerability. ASSESSMENT: BPRS, CGI, GAF, UKU, and DAI were administered at baseline and months 1, 3, and 6. STATISTICAL ANALYSIS: the Wilcoxon's T, Friedman's test, and Cochran's Q have been employed. RESULTS: Mean total dose of risperidone: 5.5 mg/d (SD 2.4). Scores on BPRS, CGI, GAF, UKU, DAI showed statistically significant improvements (p<0.0001). Significant decrease in the proportion of patients using anticholinergic drugs to control extrapyramidal symptoms and in the rate of hospitalizations. CONCLUSIONS: patients benefited from the change to risperidone in terms of efficacy, tolerance, compliance and admissions. Depot neuroleptic treated schizophrenic patients can benefit from treatment change to an oral atypic antipsychotic like risperidone to ease compliance, illness outcome and patient community integration.

Adolescent↗

PubMedDate not supplied

[Risperidone in the treatment of psychotic patients with opiate abuse and dependence].

INTRODUCTION: 180 psychotic patients with opiate dependence and abuse (ICD-10) were included in an open label study. The study objectives were to evaluate safety and efficacy of risperidone for a six month follow-up period. The total mean dose was 4.4 (SD: 2.4 mg/daily; range: 0.5-12 mg/daily). METHODS: BPRS, CGI and DDS-SV were used to assess efficacy and UKU subscale for neurological side effects and spontaneous reports for safety. RESULTS: Risperidone treatment improved symptoms, disability of the included patients with a significant reduction in the mean total scores of BPRS, CGI and DDS-SV observed from the first month of treatment onwards. Risperidone also reduced illegal opiate abuse patients from 39% basedate to 18% at month 6. There was a significant reduction (p< 0.0001) in the total UKU subscale for neurological side effects scores from visit 1 onwards for studied sample. Risperidone was well tolerated by the study patients. From 165 elegible patients, just 10 (6.1%) discontinued treatment due to adverse reactions, 94% of the patients did not suffer any adverse event; the most frequent adverse events according spontaneous reports were extrapyramidal effects (3%) and anxiety (1.8%). DISCUSSION: Risperidone improved disability, psychotic symptoms and tolerability of these patients. Those results could mean an outstanding breakthrough in the treatment of these type of disorders and, if it is confirmed that risperidone can lead to abstinence, we would be before a new line of treatment for dual pathology.

Adolescent↗

PubMedDate not supplied

[Impact of olanzapine on quality of life of patients with schizophrenia: one-year follow-up with the Seville Quality of Life Questionnaire].

INTRODUCTION: Our objective is to present the impact on quality of life of long-term olanzapine treatment in a significant number of schizophrenics as determined by the Seville Quality of Life Questionnaire (SQLQ), an instrument that addresses the aspects that particularly affect these patients, and to evaluate the sensitivity of this instrument to the changes induced by this treatment. METHODS: Three hundred and seventy two patients with the diagnosis of schizophrenia as per the ICD-10 classification were evaluated in a 1 year prospective study after switching to olanzapine. The SQLQ, Lehman's structured interview and short version of the discapacity assessment scale were used to evaluate patient's subjective experience; in addition, other instruments were used to evaluate psychopathology. RESULTS: Significant increases in the scores of the favorable scale and decreases in the unfavorable scale of the SQLQ were found. There were also significant improvements in quality of life as measured with Lehman's structured interview. This improvement continued until the end of the 1 year follow-up after switching to olanzapine. Both instruments show a good correlation. Changes in psychopathology were also remarkable, including the negative symptoms. CONCLUSIONS: The SQLQ has proven to be a sensitive instrument to measure quality of life in schizophrenic patients treated with olanzapine. It focuses on aspects that are relevant for patients that were frequently overlooked by treating physicians. This drug has been proven to have a favorable subjective impact upon patients, besides improving psychopathology.

Adolescent↗

PubMedDate not supplied

[Study of effectiveness of craving control with topiramate in patients with substance dependence disorders].

INTRODUCTION: Effectiveness and tolerability of topiramate at 3 and 6 months was assessed in patients requesting dehabituation programs. METHODS: Observational, prospective, national and multicenter study of 6 months, in patients on treatment with topiramate, who fulfilled criteria for dependence of opiates according to ICD-10 participating in therapeutic programs of dehabituation, without concomitant psychiatric illnesses and any responsible relative. Main measures of effectiveness were retention rates, alcohol consumption and other illicit drugs by urine tests (opiates, cannabis, cocaine) and treatment needs by EuropASI scale. Other parameters were HAM-D, DAS-SV and SF-36. RESULTS: Patients with consumption by urine tests decreased from 94.1 % (n = 64) at baseline to 39.6 % (n = 19) after 6 months of treatment, as was seen by means of the mean score in EuropASI scale, for all substances except methadone. No consumption was accompanied by a low rate of relapse of 33.3 % at 6 months. Twenty one patients had adverse reactions (28 %). The most frequent adverse reactions were somnolence (n = 9; 12 %), paraesthesia (n = 5; 6.7 %) and depression (n = 4; 5.3 %). CONCLUSIONS: In real clinical practice, topiramate showed a good response with a relevant decrease of percent of patients with abuse or consumption, and a satisfactory tolerability profile for the treatment of patients with dependence on heroine, cocaine, and other opiates, showing better outcomes than those obtained in previous trials.

Adult↗